Montelukast Noridem Enterprises

Montelukast, the active ingredient in Montelukast Noridem Enterprises, is a leukotriene receptor antagonist presented as a tablet for oral use. It treats asthma and allergic rhinitis in adults and children.

GNH USA supplies Montelukast Noridem Enterprises as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is a leukotriene receptor antagonist used to manage airway inflammatory conditions.

- Asthma: improves long‑term control and reduces the frequency of exacerbations. - Allergic rhinitis: relieves nasal congestion, sneezing and itchy eyes associated with seasonal or perennial allergies. - Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs after physical activity.

Montelukast may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort or cramping. - Cough: transient irritation of the throat. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Allergic reactions: rash, urticaria or anaphylaxis. - Neuropsychiatric events: mood changes, depression or suicidal thoughts. - Angioedema: swelling of the face, lips or tongue. - Hepatic enzyme elevation: abnormal liver function tests.

Before prescribing Montelukast, clinicians should consider several safety aspects.

- Assess asthma control: ensure baseline control before adding therapy. - Monitor neuropsychiatric symptoms: watch for mood changes or suicidal ideation. - Use caution in hepatic impairment: dose adjustment may be required. - Avoid in patients with known hypersensitivity to montelukast or any tablet excipients. - Store at room temperature: keep in the original pack, protect from moisture.

Montelukast can interact with other medicines, affecting its plasma levels or therapeutic effect.

Major Interactions (Avoid): - Ritonavir: may increase montelukast exposure, raising risk of side effects. - Phenobarbital: may reduce montelukast effectiveness by enhancing metabolism. - Carbamazepine: may lower plasma concentrations, diminishing clinical benefit.

Moderate Interactions (Monitor Closely): - Fluconazole: can raise montelukast levels; monitor for adverse effects. - Erythromycin: may increase exposure; observe for toxicity. - Warfarin: potential effect on INR; regular coagulation monitoring is advised.